Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H. S. Gour Vishwavidyalaya, Sagar 470003, M.P., India.
J Biomed Nanotechnol. 2011 Feb;7(1):130-1. doi: 10.1166/jbn.2011.1235.
The objective of the study was to develop lipid drug conjugate nanoparticles (LDC-NPs) of anticancer drug methotrexate (MTX) for oral delivery that faces problems of low and variable bioavailability. The MTX loaded LDC-NPs significantly enhanced bioavailability and reduced MTX associated gastrointestinal toxicity even in higher doses recommended for anticancer therapy.
本研究旨在开发载有抗癌药物甲氨蝶呤 (MTX) 的脂质药物偶联纳米粒 (LDC-NPs)，用于口服递送，但存在生物利用度低且变异性大的问题。载有 MTX 的 LDC-NPs 可显著提高生物利用度，并降低 MTX 相关的胃肠道毒性，即使在推荐用于癌症治疗的较高剂量下也是如此。
